454 related articles for article (PubMed ID: 27655895)
21. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
Dixon ZA; Nicholson L; Zeppetzauer M; Matheson E; Sinclair P; Harrison CJ; Irving JA
Haematologica; 2017 Apr; 102(4):736-745. PubMed ID: 27979926
[TBL] [Abstract][Full Text] [Related]
22. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
Li B; Brady SW; Ma X; Shen S; Zhang Y; Li Y; Szlachta K; Dong L; Liu Y; Yang F; Wang N; Flasch DA; Myers MA; Mulder HL; Ding L; Liu Y; Tian L; Hagiwara K; Xu K; Zhou X; Sioson E; Wang T; Yang L; Zhao J; Zhang H; Shao Y; Sun H; Sun L; Cai J; Sun HY; Lin TN; Du L; Li H; Rusch M; Edmonson MN; Easton J; Zhu X; Zhang J; Cheng C; Raphael BJ; Tang J; Downing JR; Alexandrov LB; Zhou BS; Pui CH; Yang JJ; Zhang J
Blood; 2020 Jan; 135(1):41-55. PubMed ID: 31697823
[TBL] [Abstract][Full Text] [Related]
23. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
24. Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
Dieck CL; Ferrando A
Blood; 2019 May; 133(21):2263-2268. PubMed ID: 30910786
[TBL] [Abstract][Full Text] [Related]
25. Analysis of RAS oncogene mutations in human lymphoid malignancies.
Neri A; Knowles DM; Greco A; McCormick F; Dalla-Favera R
Proc Natl Acad Sci U S A; 1988 Dec; 85(23):9268-72. PubMed ID: 3057505
[TBL] [Abstract][Full Text] [Related]
26. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
27. Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias.
Schmitt MW; Pritchard JR; Leighow SM; Aminov BI; Beppu L; Kim DS; Hodgson JG; Rivera VM; Loeb LA; Radich JP
Clin Cancer Res; 2018 Nov; 24(21):5321-5334. PubMed ID: 30042204
[No Abstract] [Full Text] [Related]
28. The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group.
Li X; Lin S; Liao N; Mai H; Long X; Liu L; Wu B; Chen Q; Kong Q; Kong X; Liu L; Qin J; Fang J; Zhou D
Hematol Oncol; 2024 May; 42(3):e3265. PubMed ID: 38564328
[TBL] [Abstract][Full Text] [Related]
29. Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia.
Oshima K; Zhao J; Pérez-Durán P; Brown JA; Patiño-Galindo JA; Chu T; Quinn A; Gunning T; Belver L; Ambesi-Impiombato A; Tosello V; Wang Z; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Balbin M; Nicolas C; Gastier-Foster JM; Devidas M; Loh ML; Paietta E; Tallman MS; Rowe JM; Litzow M; Minden MD; Meijerink J; Rabadan R; Ferrando A
Nat Cancer; 2020 Nov; 1(11):1113-1127. PubMed ID: 33796864
[TBL] [Abstract][Full Text] [Related]
30. Mutational analysis of the N-ras gene in acute lymphoblastic leukemia: a study of 125 Japanese pediatric cases.
Yokota S; Nakao M; Horiike S; Seriu T; Iwai T; Kaneko H; Azuma H; Oka T; Takeda T; Watanabe A; Kikuta A; Asami K; Sekine I; Matsushita T; Tsuhciya T; Mimaya J; Koizumi S; Miyake M; Nishikawa K; Takaue Y; Kawano Y; Iwai A; Ishida Y; Matsumoto K; Fujimoto T
Int J Hematol; 1998 Jun; 67(4):379-87. PubMed ID: 9695411
[TBL] [Abstract][Full Text] [Related]
31. Mutational dynamics of early and late relapsed childhood ALL: rapid clonal expansion and long-term dormancy.
Spinella JF; Richer C; Cassart P; Ouimet M; Healy J; Sinnett D
Blood Adv; 2018 Feb; 2(3):177-188. PubMed ID: 29365312
[TBL] [Abstract][Full Text] [Related]
32. Detection of chemotherapy-resistant patient-derived acute lymphoblastic leukemia clones in murine xenografts using cellular barcodes.
Jacobs S; Ausema A; Zwart E; Weersing E; de Haan G; Bystrykh LV; Belderbos ME
Exp Hematol; 2020 Nov; 91():46-54. PubMed ID: 32946982
[TBL] [Abstract][Full Text] [Related]
33. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.
Kaufman Y; Drori S; Cole PD; Kamen BA; Sirota J; Ifergan I; Arush MW; Elhasid R; Sahar D; Kaspers GJ; Jansen G; Matherly LH; Rechavi G; Toren A; Assaraf YG
Cancer; 2004 Feb; 100(4):773-82. PubMed ID: 14770434
[TBL] [Abstract][Full Text] [Related]
34. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
35. RAS and FMS mutations following cytotoxic therapy for childhood acute lymphoblastic leukaemia.
Taylor C; McGlynn H; Carter G; Baker AH; Warren N; Ridge SA; Owen G; Thompson E; Thompson PW; Jacobs A
Leukemia; 1995 Mar; 9(3):466-70. PubMed ID: 7885045
[TBL] [Abstract][Full Text] [Related]
36. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
37. Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.
Liang DC; Chen SH; Liu HC; Yang CP; Yeh TC; Jaing TH; Hung IJ; Hou JY; Lin TH; Lin CH; Shih LY
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28853218
[TBL] [Abstract][Full Text] [Related]
38.
Contreras Yametti GP; Robbins G; Chowdhury A; Narang S; Ostrow TH; Kilberg H; Greenberg J; Kramer L; Raetz E; Tsirigos A; Evensen NA; Carroll WL
Leuk Lymphoma; 2024 Jan; 65(1):78-90. PubMed ID: 37874744
[TBL] [Abstract][Full Text] [Related]
39. The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia.
Mansur MB; Furness CL; Nakjang S; Enshaei A; Alpar D; Colman SM; Minto L; Irving J; Poole BV; Noronha EP; Savola S; Iqbal S; Gribben J; Pombo-de-Oliveira MS; Ford TM; Greaves MF; van Delft FW
Cancer Med; 2021 Jul; 10(14):4864-4873. PubMed ID: 34080325
[TBL] [Abstract][Full Text] [Related]
40. Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.
Lu SX; Abdel-Wahab O
Proc Natl Acad Sci U S A; 2016 Oct; 113(40):11071-11073. PubMed ID: 27663730
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
